Navigation Links
British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection
Date:1/28/2009

University of Nottingham Scientists Leading Major Study into Lethal 'Super' Strains of C.difficile

CHICAGO, Jan. 28 /PRNewswire/ -- The British Midlands Development Corporation today announced that scientists at The University of Nottingham are leading a major European study to unravel the genetic code of one of the most lethal strains of hospital acquired infections.

The $4.5 million, three-year study will use gene knock-out technology developed in Nottingham to study the function of genes in a 'super' strain of the bacteria Clostridium difficile, to discover why it causes more severe disease, kills more people, is harder to eradicate and more resistant to antibiotics.

It is hoped that the study will lead to better tests to diagnose 'super' strains of C.difficile, more effective treatments and, possibly, even a vaccine to protect against the disease.

Currently, scientists know that the bacteria cause disease by sticking to epithelial cells of the gut lining and releasing two toxins that damage cells leading to the tell-tale symptom of severe diarrhea. However, there is very little known about the ways in which the bacteria operate and why the strain should be more severe than its less virulent cousins.

Leading the study, Professor Nigel Minton in The University of Nottingham's School of Molecular Medical Sciences, said: "These hypervirulent organisms seem to be taking over as the dominant strain in outbreaks and, worryingly, there are only two antibiotics which are still effective against them. There is a very real danger that total resistance may arise, and if that happens then this will become an extremely serious problem.

"The idea behind the study is that we investigate the genomes of the hypervirulent strains and identify their differences to the so-called standard strains. In this way, we should get a clearer picture of the whole range of factors involved in its spread and the way in which it causes disease."

The Centre for Healthcare Associated Infections (CHAI) was established at the University of Nottingham in late 2006. CHAI consists of researchers from the University, together with clinical colleagues from Nottingham University Hospitals NHS Trust, which allows a unique holistic approach to HAI research. Researchers in CHAI have made major breakthroughs in our understanding of the basic biology of C.difficile and MRSA that will assist efforts to develop new antibiotics and better diagnostic tests to identify these pathogens.

During the three-year study, scientists at Nottingham will use a technology called ClosTron to produce mutant versions of the hypervirulent strains. They will knock out genes one by one and then compare the mutant version to the standard organism to assess the function of each cell.

The British Midlands region, comprising the East and the West Midlands in the centre of the UK, is at the heart of the UK's biopharma industry, which is the largest in Europe, generating revenues in excess of $8.6 billion per year. Strong links between academia and industry across the region, have resulted in the creation of many dedicated science parks and incubators. These include BioCity Nottingham, the largest bioscience innovation and incubation centre in the UK.

Bio-research in the Midlands has attracted a number of the world's most active pharma and biotech companies, including AstraZeneca, Aventis, Bayer, Boots, GeneSeek, Novartis, Sunrise Medical, Salts Healthcare, Bibby Sterilin, Cobra Biomanufacturing, Sterilox and 3M.

"Universities in the Midlands continue to set the bar in innovation and discovery," said Vern

Sebby, President and CEO of British Midlands Development Corporation, "The British Midlands is one of Europe's premier locations for the advancement of medicine and life sciences. All of the region's 18 universities have unique areas of scientific expertise, which fuel the region's record of innovation in the field."

About British Midlands Development Corporation

The British Midlands Development Corporation is the North American economic development agency for central England. The Midlands region is located just one hour to the north of London and includes the major commercial centers of Birmingham, Nottingham, Coventry and Northampton.

As an agency funded by the UK Government, The British Midlands Development Corporation provides specialist advice and support to North American companies seeking to establish a presence or expand a current operation in the region. The British Midlands Development Corporation provides access to business networks, details about sources for grants and funding, business support services, and information to help companies identify opportunities to develop and grow.

The British Midlands Development Corporation is based in Chicago with branch offices in Boston, Washington, DC and San Jose.

For more information, please visit our website at www.thebritishmidlands.com.

    Press Contact
    Laura Nicholas
    laura@thepontgroup.com
    646 290 5989


'/>"/>
SOURCE British Midlands Development Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The University of Nottingham in the British Midlands Announces Breakthrough in Parkinsons Disease Research
2. Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
3. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
4. University of Kansas Medical Center to Deploy Velos eResearch System-Wide
5. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
6. Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report
7. American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time
8. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
9. Queens University Chooses Xceeds Ziplex(R) System for Translational Research
10. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
11. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... YORK and GENEVA , ... announced on World Tuberculosis Day revitalizes efforts to develop ... On World Tuberculosis Day, TB Alliance and ... for the clinical development of sutezolid, an antibiotic drug ... sublicense pertains to the development of sutezolid in combination ...
(Date:3/23/2017)... MOBILE, Ala. , March 23, 2017 Mosaic Life Care, based in ... automate the patient registration process across its network of 58 clinics, located in 22 ... constantly seeking new and innovative ways to improve the delivery of health care to ... Continue Reading ... Mosaic Life Care St. Joseph ...
(Date:3/23/2017)... 2017  Transportation Insight, a multi-modal lead logistics solutions ... management firm with expertise serving clients in the food ... Zaffarano was named a 2017 Food Logistics ... the only publication exclusively dedicated to covering the movement ... "Rick has brought to Transportation Insight a wealth ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... The ... Quest Awards . The annual awards, now in their 12th year, are among ... selects the winners. , In 2016, the awards were retooled to recognize achievements in ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek Insurance Agencies, a Detroit ... business owners across eastern Michigan, is connecting with the Oxford/Orion FISH Food Pantry ... , The Oxford/Orion FISH Food Pantry works to ensure homeless, hungry, and underprivileged ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge dentists, Dr. ... for sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, ... obstructive type, is increasingly being treated at dental offices with newly developed procedures ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ( ... patients for colonoscopy at the HyGIeaCare® Center that is to be located adjacent ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a dauntless and ... “End Time GPS” is the creation of published author, Wesley Gerboth, a World ... military munitions and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God ...
Breaking Medicine News(10 mins):